Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1959

Sort by

Sort Order Select

Journal Articles

Poor prognosis is ZAP70’ed into focus in CLL

Adam J. Linley, Joseph R. Slupsky

Blood (2021) 137 (26): 3586–3587.

https://doi.org/10.1182/blood.2021011270

Published: 2021

Journal Articles

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Blood (2020) 136 (2): 210–223.

https://doi.org/10.1182/blood.2019001417

Published: 2020

Includes: Supplemental data

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Koen Debackere, Jo-Anne van der Krogt, Thomas Tousseyn, Julio Antonio Finalet Ferreiro, Katrien Van Roosbroeck, Lukas Marcelis, Carlos Graux, Daan Dierickx, Geneviève Ameye, Peter Vandenberghe, Lucienne Michaux, Jan Cools, Iwona Wlodarska

Blood (2020) 135 (8): 584–588.

https://doi.org/10.1182/blood.2019002401

Published: 2020

Includes: Supplemental data

Journal Articles

Activation of the Receptor Tyrosine Kinase (RET) By GDNF/GFRα1 Improves Cord Blood-Derived HSC in Vitro expansion and In Vivo engraftment

William Grey, PhD MSc, Rakhee Chauhan, PhD, Manuel Garcia-Albornoz, Hector Huerga Encabo, Neil McDonald, PhD, Dominique Bonnet, PhD

Blood (2019) 134 (Supplement_1): 1924.

https://doi.org/10.1182/blood-2019-121331

Published: 2019

Journal Articles

Endothelial JAK3 Expression Enhances Pro-Hematopoietic Angiocrine Function of Sinusoidal Endothelial Cells

José Gabriel Barcia Durán, BS

Blood (2019) 134 (Supplement_1): 2488.

https://doi.org/10.1182/blood-2019-122449

Published: 2019

Journal Articles

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Ivy Altomare, MD, Vadim V. Markovtsov, PhD, Leslie Todd, Dheepika Weerasinghe, PhD, Robert P. Numerof, PhD, Sandy Tong, MD, Esteban Masuda, PhD, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 4889.

https://doi.org/10.1182/blood-2019-126558

Published: 2019

Journal Articles

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Nichola Cooper, MD MRCP, Isabel Gorham, BS RN, Ann M. Lowe, MD, Robert P. Numerof, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 4800.

https://doi.org/10.1182/blood-2019-126544

Published: 2019

Journal Articles

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2019) 134 (Supplement_1): 761.

https://doi.org/10.1182/blood-2019-121521

Published: 2019

Journal Articles

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Blood (2019) 134 (Supplement_1): 755.

https://doi.org/10.1182/blood-2019-126305

Published: 2019

Journal Articles

Trimethylated H3K27, and Di- and Trimethylated H3K4 Proteomic Profiling Distinguishes Acute Lymphoid Leukemia (ALL) from Acute Myeloid Leukemia (AML) and Associates with Overall Survival and Tyrosine Kinase Inhibitor Sensitivity in Adult ALL

Anneke D. van Dijk, BS, Fieke W Hoff, BSc, Yihua Qiu, Mary Figueroa, BS, Joya Chandra, PhD, Elias Jabbour, MD, Eveline S. de Bont, MD PhD, Steven M. Kornblau, MD

Blood (2019) 134 (Supplement_1): 1460.

https://doi.org/10.1182/blood-2019-124960

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

Comprehensive Analysis of Immunophenotype and Transcriptome in Indian T-Acute Lymphoblastic Leukemia - a Prospective Study

Anita Chopra, MD DM, Deepak Verma, PhD, Shruti Kapoor, PhD, Jay Singh, MSc, Jayanth Kumar Kumar Palanichamy, MDMBBS, Raja Pramanik, MD DM, Atul Sharma, MD DM, Sameer Bakhshi, MD, Ranjit Kumar Sahoo, MDDM, Vinod Scaria, MBBS PhD, Lalit Kumar, MDDM, Sridhar Sivasubbu, PhD, Rajive Kumar, MD

Blood (2019) 134 (Supplement_1): 1467.

https://doi.org/10.1182/blood-2019-127980

Published: 2019

Journal Articles

Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma

Yixin Yao, PhD, Yang Liu, MD, Hui Zhang, Angela Leeming, Joseph Mitchell McIntosh, Preetesh Jain, MBBS,MDDM,PhD, Liang Zhang, MD PhD, Krystle Nomie, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 1506.

https://doi.org/10.1182/blood-2019-126738

Published: 2019

Journal Articles

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

Simon Rule, Martin H. Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MRCP, FRPath, PhD, Brad S. Kahl, MD, Jose Angel Hernandez-Rivas, MD PhD, Keqin Qi, PhD, Sanjay Deshpande, Lori Parisi, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 1538.

https://doi.org/10.1182/blood-2019-124691

Published: 2019

Journal Articles

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Weiguo Zhang, MD PhD, Richard Graydon, MD PhD, Vikas K Dawra, MBA, PhD, Jingdong Xie, PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1389.

https://doi.org/10.1182/blood-2019-122585

Published: 2019

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Zhenghao Chen, Gaspard Cretenet, Hanneke ter Burg, Gabriela Andrejeva, Jeffrey C Rathmell, Francesco Forconi, MD DM, PhD FRCPath, Gerritje J. W. van der Windt, Arnon P. Kater, Eric Eldering

Blood (2019) 134 (Supplement_1): 479.

https://doi.org/10.1182/blood-2019-123005

Published: 2019

Journal Articles

Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)

Paula De Melo Campos, MD, Katia B Pagnano, MD PhD, Rubia Mancuso, Francisco Breno S. Teófilo, Juan L Coelho-Silva, BSc, MSc, Fernanda I Della Via, MSc, Leandro Luiz Lopes Freitas, MD PhD, Hernandes F. Carvalho, PhD, Fernando Ferreira Costa, MD PhD, Fabiola Traina, MD PhD, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 554.

https://doi.org/10.1182/blood-2019-130648

Published: 2019

Journal Articles

Ibrutinib in Combination with Venetoclax Decreases Mitochondrial Bioenergetics through the Impaired BTK, AKT and AMPK/SIRT/PGC-1α Signaling Pathway in CLL

Subir Roy Chowdhury, MD PhD, Amandeep Singh, MSc, Edwin Nguyen, Aaron Marshall, PhD, James B. Johnston, MD, Spencer Bruce Gibson, PhD, Versha Banerji, MD

Blood (2019) 134 (Supplement_1): 1282.

https://doi.org/10.1182/blood-2019-127562

Published: 2019

NARROW

Poor prognosis is ZAP70’ed into focus in CLL

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Activation of the Receptor Tyrosine Kinase (RET) By GDNF/GFRα1 Improves Cord Blood-Derived HSC in Vitro expansion and In Vivo engraftment

Endothelial JAK3 Expression Enhances Pro-Hematopoietic Angiocrine Function of Sinusoidal Endothelial Cells

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Phase 2 Results of the iR 2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Trimethylated H3K27, and Di- and Trimethylated H3K4 Proteomic Profiling Distinguishes Acute Lymphoid Leukemia (ALL) from Acute Myeloid Leukemia (AML) and Associates with Overall Survival and Tyrosine Kinase Inhibitor Sensitivity in Adult ALL

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Comprehensive Analysis of Immunophenotype and Transcriptome in Indian T-Acute Lymphoblastic Leukemia - a Prospective Study

Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma

Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia

Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)

Ibrutinib in Combination with Venetoclax Decreases Mitochondrial Bioenergetics through the Impaired BTK, AKT and AMPK/SIRT/PGC-1α Signaling Pathway in CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only